Member Info for Retireby40

I believe GB was highlighting the folly of obsessing with the domestic market when we are well placed in China and US which are much larger markets. That said we are clearly known domestically given the RNS as mentioned. We are in phase 3 testing here and have been working with UK unis and water cos. Given a choice I’d rather dominate in China and US and my bet is China would be the first to write real-time testing into its legislation/regulations as opposed to our joke gov. Well unless GB knows Tory politicians or donates!

I’m with HSBC and the money has gone but shares not appeared. They’ll no doubt pop up in the coming days.

Great to hear how the money is being spent and although I’m sure it’ll take a while to develop the live product will be something else.

Just sit back and watch them dominate the space as the first on the block and create a lot of shareholder value.

Really like the CEO and think we’ll see some decent revenue growth next year. Onwards and upwards.

The Tories will claim little England invented it and all is well being isolationist ******s.

This is my largest holding by some way.

Sorry for the cross-ramp but anyone with time at 1pm on Thursday listen in on this -

https://us02web.zoom.us/webinar/register/5015984377728/WN__F1KkAoWQfa_mDzjgrr8LQ

My holding in DVRG is worth double what I have in MIRI but the potential for both is massive.

Back to here we should have a trading update first couple of weeks in Jan which will confirm £4m and hey hopefully 5-10% more but let’s say £4.2m and I’m really excited by the guidance which I assume won’t include the 2 products undergoing testing. As mentioned before we guided £6m FY21 in Jan this year (excluding MWG) but given we’ve done £3m H2 and possibly £2m Q4 given it’s our largest Q we could be going for double organic to £8m and with MWG double figures and hopefully profitability.

Assuming the testing goes to plan, just real-time monitoring, and we only include 3,000 units to retrofit it could have a significant impact on revenue and recurring revenues for AI. If we only make, bottom line, so profit £1,000 extra per annum for each unit that’s an extra £3m to the bottom line. It could be an extra £15m in revenue but who knows I just wanted to point out the potential.

Potential here is massive.

I believe there are a few other versions of lab made human skin but ours is the only one that is true to life as is can host bacteria, fungi etc and the others are not able to so do not truly mimic the Microbiome like we do. I haven’t fully researched but I’m not sure who else can offer cloning for trials. I’m certain of not being able to host bacteria etc.

To be fair the more accessible it is the higher the uptake.

Really looking forward to 2021 with DVRG continuing its growth.

Wow and $70 seems too cheap! Surely can go for £95/$95.

Given the £4m guidance was given early Jan the fact that we are achieving this is spectacular IMO. So many cos missed guidance due to Covid and let’s say we get £4.2m so 5% more that’s still superb and 20% of the entire revenue last year.

We did £1m H1 which was FY19 and we know Q4 is the best yet so Q3 could be £1m say and Q4 £2m so clear momentum and double what we did last year.

Clearly the new service has quickly gained traction in its soft launch and one imagines once its properly rolled out next year it’ll be another Decent revenue Generator.

Hopefully the guidance we get in Jan will get us to profitability. We guided £4m FY20 and £6m FY21 excluding MWG so perhaps excluding MWG £6m guided could increase by 1/3rd to £8m so double this year and with MWG we are looking at double figure millions for revenue.

See page 21 -
https://www.deepverge.com/wp-content/uploads/2020/01/Integumen_INITIATION_FINAL.pdf

https://mcusercontent.com/d9ebd7c1aa0f3dbc5fab42eca/files/27f2fb01-ce85-4a33-91aa-46ad583b03ec/DeepVergeplc_Research_Update_11_December_2020__FINAL_BG.pdf

I particularly like this which will be the marketing departments dream.

Significantly, once the University of Aberdeen trials have completed and been verified, labelling authorisation could also be formally granted

Making claims and saying it’s been scientifically proven to do XYZ is a lot stronger than 9 out of 10 people surveyed thought XYZ.

That can apply to killing Covid, reducing dry skin for dandruff shampoo for instance and many more.

I think it was an intended put down (deramp) but pretty ill thought out.

Exactly, 40 or so targets I believe so not Covid reliant. Same applies to the real-time monitoring which is obvious as it’s been in development for a few years!

What are you in about? 3 and a half weeks ago -

Update on detection of COVID-19 products

First deployments of Microtox PD in Ireland

License of patented breathalyser for Microtox BT COVID-19 breath test and initiation of Phase 3 field trials

DeepVerge has commenced deployment of near-source wastewater contamination test equipment ("Microtox PD") into water treatment plants in Ireland, with first shipments to China and the US expected by year-end.

Microtox PD units, retrofitted with AI based optofluidic pathogen identification scanners, are also being shipped to the University of Aberdeen CAT3 laboratory, adding to the ongoing trials with the live SARS-CoV-2, supplied by Public Health England.

In addition, DeepVerge has agreed to license a patented breathalyser from PulMoBioMed Limited ("PBM"), a spin-out technology company of Northumbria University, to capture SARS-CoV-2 particles in breath condensate for the DeepVerge optofluidic breath test ("Microtox BT").

Phase 3 field trials are expected to begin shortly at multiple sites in Northern England. In collaboration with EcoWaterOS consortia partners, aggregated anonymised data will provide datasets for AI model simulations from human volunteers who will undergo COVID-19 testing with a combination of Microtox BT, a lateral flow antigen test and a rt-PCR test. Sufficient datasets are anticipated to be complete early in 2021.

Gerard Brandon, CEO of DeepVerge, Commented:

"Phase 3 field trial testing is the last step to establish permanent anonymised mass surveillance of dangerous pathogens in wastewater, in real-time. The field trials will combine the deployment of Microtox PD wastewater units and daily testing of individual volunteers with a Microtox BT breathalyser test, a lateral flow test and a PCR test. The data from these tests are expected to simultaneously identify the source of COVID-19 cases, identify COVID-19 clusters, and indicate the size of each cluster in real-time. As the data grows, AI will offer the potential to predict the trajectory of growth of future clusters of Sars-CoV-2 or any future dangerous pathogen. As we progress towards commercialisation, PulMoBioMed's patented technology will enable a quick roll-out of our Microtox BT breath test once field trials have completed. We look forward to reporting the results in due course."

Dr Sterghios Moschos, MD of PulMoBioMed, added:

"We are delighted to be working with the team at DeepVerge and adding our PBM-Hale device for collecting exhaled breath condensate to the Microtox BT Project, and look forward to combining our respective technologies to deliver a real-time solution for the mass surveillance of COVID-19."

Love the name Pickuzawinnah!

Sensyne has their success priced in to their valuation whereas we have none. I think the trading update next year confirming £4m with guidance in excess of £10m in organic growth will get things moving. These clients will be using our services more and more so recurring revenues with great margins and of course new clients to be won.

Remember China will be changing its regs and we have a foot in the door. A massive 2021 incoming. Oh and I think real-time monitoring will accelerate our growth in terms of revenue but also getting on more radars.

Think of the total address key market now given the diverse range of products we’re now able to test on. As well as existing products it’ll be great for NPD.

I love this -

The new R&D service adds to the existing client offering. It increases revenue per client and delivers higher value test services on ingredients used in an expansive range of products - from anti-viral, to shampoos to babies' nappies. The new service replicates skin conditions of the scalp, face, mouth and abdomen. It also utilises AI which has significantly improved the speed and accuracy of testing ingredients on virtual skin models.

Also this from GB and given it’s only on soft launch to have generated £400k in this Q with 10 new clients the potential is mind boggling.

While we will fully launch the product at conferences across all regions in 2021, it has already resulted in significant interest and orders from existing and new clients as well as from new clients in new sectors/markets.

Ha, I’m not invested in them but pointing out the disparity in valuations. To be fair they look like a decent business with potential but with turnover half ours, £22m loss and valued 4 x what we are it’s crazy. I’m sure come early next year we’ll be nearer to their valuation!

Check out Sensyne Health who look like a decent co with a bright future, much like DVRG’s. Also in AI and in healthcare and life science sector with some great clients and partners, again like DVRG. Like us they are at an early stage so will grow and make losses but wow they’re valued some 4X us at over £160m with turnover (to Oct 2020) of circa £2m and losses of £22m (they have over £30m in cash which is clearly needed).
We are valued at £40m and will hopefully turnover over 25% of that and be profitable next year. We are a tech/AI co and the valuations of PLCs use different metrics (especially in the US). I think next year after trading update and yearly guidance we’ll see us nearer to £100m than £50m in short order.

From lse-

We do not rest on our laurels and the soft launch has resulted in £400k and 10 new clients this Q. Wow. Very diverse products too from anti-virals to shampoos and to nappies. The potential here is clearly massive and in addition to existing clients.
Remember now we have feet on the ground in China and the US now. 2021 is going to be massive without anything Covid related. That said the 2 products in testing are beyond Covid anyway but even without them labskin alone will generate superb revenues.
Really looking forward to Jan’s trading update and forecast which if is published before phase 2 testing has completed it probably won’t include anything from them. Cannot wait. What’s our market cap? I’ve a fuzzy head but will look at some other tech/AI PLCs for starters.

Fair enough and have a good end to a pretty bad year.

Given the space we are operating in, our IP and even with the organic growth alone I believe we will be rated a lot higher next year and will attract IIs. I doubt there will be any news this year but who knows, could get more large sign ups on labskin but I assume then next update will be early Jan confirming £4m FY and hopefully we get 2021 guidance soon after for the enlarged group. Testing will still be underway so I’m not sure it’d be wise for them to include any revenue from products under test.